BACKGROUND: Early detection of individuals at high risk for chronic kidney disease (CKD) may aid prevention. Urinary levels of trefoil factor 3 (TFF3) are associated with acute kidney injury in animal models, but the association of TFF3 levels with incident CKD in humans is unknown. METHODS: We conducted a case-control study nested within the Atherosclerosis Risk in Communities (ARIC) Study and the ARIC Carotid MRI Study to determine whether urinary TFF3 levels predict incident CKD over 8.6 years of follow-up. A total of 143 participants with incident CKD (eGFR decreasing by ≥25% to <60 ml/min/1.73 m(2)) were matched on age, sex and race to 143 non-cases. RESULTS: Higher TFF3 levels at baseline were strongly associated with Black race, diabetes (both p = 0.002), and antihypertensive medication use (p = 0.02). Compared to participants with TFF3 levels in the lowest quartile, the odds ratio (OR) of incident CKD was 1.84 (95% confidence interval (CI): 0.80, 4.22) for individuals with TFF3 levels in the second quartile, 2.43 (95% CI: 1.06, 5.53) for the third quartile, and 2.77 (95% CI: 1.22, 6.28) for the fourth quartile (p trend = 0.02). Adjustment for covariates, including urinary albumin: creatinine ratio, did not markedly change the associations. Twofold higher TFF3 levels were strongly associated with incident CKD after adjustment for CKD risk factors (adjusted OR = 1.35; 95% CI: 1.11, 1.64). CONCLUSIONS: Higher urinary TFF3 levels may indicate ongoing repair of damage in the kidney. Additional studies are needed to confirm whether TFF3 can be useful as a marker of increased risk for CKD.
BACKGROUND: Early detection of individuals at high risk for chronic kidney disease (CKD) may aid prevention. Urinary levels of trefoil factor 3 (TFF3) are associated with acute kidney injury in animal models, but the association of TFF3 levels with incident CKD in humans is unknown. METHODS: We conducted a case-control study nested within the Atherosclerosis Risk in Communities (ARIC) Study and the ARIC Carotid MRI Study to determine whether urinary TFF3 levels predict incident CKD over 8.6 years of follow-up. A total of 143 participants with incident CKD (eGFR decreasing by ≥25% to <60 ml/min/1.73 m(2)) were matched on age, sex and race to 143 non-cases. RESULTS: Higher TFF3 levels at baseline were strongly associated with Black race, diabetes (both p = 0.002), and antihypertensive medication use (p = 0.02). Compared to participants with TFF3 levels in the lowest quartile, the odds ratio (OR) of incident CKD was 1.84 (95% confidence interval (CI): 0.80, 4.22) for individuals with TFF3 levels in the second quartile, 2.43 (95% CI: 1.06, 5.53) for the third quartile, and 2.77 (95% CI: 1.22, 6.28) for the fourth quartile (p trend = 0.02). Adjustment for covariates, including urinary albumin: creatinine ratio, did not markedly change the associations. Twofold higher TFF3 levels were strongly associated with incident CKD after adjustment for CKD risk factors (adjusted OR = 1.35; 95% CI: 1.11, 1.64). CONCLUSIONS: Higher urinary TFF3 levels may indicate ongoing repair of damage in the kidney. Additional studies are needed to confirm whether TFF3 can be useful as a marker of increased risk for CKD.
Authors: Jackson T Wright; George Bakris; Tom Greene; Larry Y Agodoa; Lawrence J Appel; Jeanne Charleston; DeAnna Cheek; Janice G Douglas-Baltimore; Jennifer Gassman; Richard Glassock; Lee Hebert; Kenneth Jamerson; Julia Lewis; Robert A Phillips; Robert D Toto; John P Middleton; Stephen G Rostand Journal: JAMA Date: 2002-11-20 Impact factor: 56.272
Authors: Josef Coresh; Brad C Astor; Geraldine McQuillan; John Kusek; Tom Greene; Frederick Van Lente; Andrew S Levey Journal: Am J Kidney Dis Date: 2002-05 Impact factor: 8.860
Authors: Caroline S Fox; Martin G Larson; Eric P Leip; Bruce Culleton; Peter W F Wilson; Daniel Levy Journal: JAMA Date: 2004-02-18 Impact factor: 56.272
Authors: Conall M O'Seaghdha; Shih-Jen Hwang; Martin G Larson; James B Meigs; Ramachandran S Vasan; Caroline S Fox Journal: J Am Soc Nephrol Date: 2013-08-29 Impact factor: 10.121
Authors: Carmen A Peralta; Ronit Katz; Joseph V Bonventre; Venkata Sabbisetti; David Siscovick; Mark Sarnak; Michael G Shlipak Journal: Am J Kidney Dis Date: 2012-06-30 Impact factor: 8.860
Authors: Yeoungjee Cho; David W Johnson; David A Vesey; Carmel M Hawley; Margaret Clarke; Nicholas Topley Journal: Perit Dial Int Date: 2014-04-07 Impact factor: 1.756
Authors: Morgan E Grams; Aditya Surapaneni; Jingsha Chen; Linda Zhou; Zhi Yu; Diptavo Dutta; Paul A Welling; Nilanjan Chatterjee; Jingning Zhang; Dan E Arking; Teresa K Chen; Casey M Rebholz; Bing Yu; Pascal Schlosser; Eugene P Rhee; Christie M Ballantyne; Eric Boerwinkle; Pamela L Lutsey; Thomas Mosley; Harold I Feldman; Ruth F Dubin; Peter Ganz; Hongzhe Lee; Zihe Zheng; Josef Coresh Journal: J Am Soc Nephrol Date: 2021-09 Impact factor: 14.978
Authors: Gearoid M McMahon; Matthias Olden; Maija Garnaas; Qiong Yang; Xuan Liu; Shih-Jen Hwang; Martin G Larson; Wolfram Goessling; Caroline S Fox Journal: J Am Soc Nephrol Date: 2014-05-29 Impact factor: 10.121
Authors: Vasantha Jotwani; Rebecca Scherzer; Alison Abraham; Michelle M Estrella; Michael Bennett; Prasad Devarajan; Kathryn Anastos; Mardge H Cohen; Marek Nowicki; Anjali Sharma; Mary Young; Phyllis C Tien; Carl Grunfeld; Chirag R Parikh; Michael G Shlipak Journal: Antivir Ther Date: 2013-08-23